Literature DB >> 21308838

The thymic-thoracic ratio in fetal heart defects: a simple way to identify fetuses at high risk for microdeletion 22q11.

R Chaoui1, K-S Heling, A Sarut Lopez, G Thiel, K Karl.   

Abstract

OBJECTIVES: To establish reference ranges for the fetal thymic-thoracic ratio (TT-ratio) and to compare results with those from fetuses with congenital heart defects (CHD) with and without microdeletion 22q11 (del.22q11), a condition known to be associated with a hypoplastic thymus.
METHODS: TT-ratio was defined as the quotient of the anteroposterior thymic to the intrathoracic mediastinal diameters measured in the three vessels and trachea view. This ratio was measured in a prospective cross-sectional study of 302 normal healthy fetuses between 15 and 39 weeks' gestation. The study group comprised two groups: one group (CHDn) consisted of 90 fetuses with CHD and a normal karyotype with no del.22q11 and the other group (CHD(22)) included 20 fetuses with CHD and a normal karyotype but with proven del.22q11.
RESULTS: The TT-ratio of the normal fetuses did not show any statistically significant change during gestation, with a mean value of 0.44. The values of all 90 fetuses of the CHDn group were within the normal range and no different from normal fetuses. However, 19 of the 20 (95%) fetuses in the CHD(22) group had a significantly smaller TT-ratio (P < 0.001) compared with both the CHDn group and the normal fetuses, having a mean value of 0.25.
CONCLUSIONS: The TT-ratio is reliable and easy to obtain during fetal echocardiography. Fetuses with CHD and a low TT-ratio can be considered at high risk of having microdeletion del.22q11.
Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21308838     DOI: 10.1002/uog.8952

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  5 in total

1.  Expanding the fetal phenotype: Prenatal sonographic findings and perinatal outcomes in a cohort of patients with a confirmed 22q11.2 deletion syndrome.

Authors:  Erica Schindewolf; Nahla Khalek; Mark P Johnson; Juliana Gebb; Beverly Coleman; Terrence Blaine Crowley; Elaine H Zackai; Donna M McDonald-McGinn; Julie S Moldenhauer
Journal:  Am J Med Genet A       Date:  2018-07-28       Impact factor: 2.802

2.  Neuropsychiatric aspects of 22q11.2 deletion syndrome: considerations in the prenatal setting.

Authors:  Anne S Bassett; Gregory Costain; Christian R Marshall
Journal:  Prenat Diagn       Date:  2016-11-14       Impact factor: 3.050

3.  Prenatal sonographic and cytogenetic/molecular findings of 22q11.2 microdeletion syndrome in 48 confirmed cases in a single tertiary center.

Authors:  Tugba Sarac Sivrikoz; Seher Basaran; Recep Has; Birsen Karaman; Ibrahim Halil Kalelioglu; Melike Kirgiz; Umut Altunoglu; Atil Yuksel
Journal:  Arch Gynecol Obstet       Date:  2021-06-18       Impact factor: 2.344

4.  Utility of Measuring Fetal Cavum Septum Pellucidum (CSP) Width During Routine Obstetrical Ultrasound for Improving Diagnosis of 22q11.2 Deletion Syndrome: A Case-Control Study.

Authors:  Christy L Pylypjuk; Shiza F Memon; Bernard N Chodirker
Journal:  Appl Clin Genet       Date:  2022-07-26

5.  Prenatal screening of DiGeorge (22q11.2 deletion) syndrome by abnormalities of the great arteries among Thai pregnant women.

Authors:  Kuntharee Traisrisilp; Fuanglada Tongprasert; Kasemsri Srisupundit; Suchaya Luewan; Theera Tongsong
Journal:  Obstet Gynecol Sci       Date:  2020-04-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.